Background
Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis requiring hospital admission in infants. Maternal RSV vaccination was introduced in the UK in September 2024 to reduce severe RSV disease during early infancy. This retrospective study evaluated the clinical characteristics of children admitted with RSV-positive bronchiolitis in relation to maternal RSV immunisation status and the association between maternal RSV vaccination and respiratory support and length of hospital stay.
Methods
Children admitted with laboratory-confirmed RSV-positive bronchiolitis between October 2025 and February 2026 across two hospitals within the Trust were included in the study. Maternal RSV vaccination status was obtained from BadgerNet electronic records. Children’s data were collected from electronic patient records. Data collected included age at presentation, respiratory support, and duration of hospital stay. Respiratory support was categorised as no respiratory support, low-flow oxygen (LFO₂), or high-flow nasal oxygen (AIRVO).
Results
A total of 97 children were admitted with RSV-positive bronchiolitis. Maternal RSV vaccination status was available for 90 children; 37 (41%) were born to vaccinated mothers and 53 (59%) to unvaccinated mothers.
In the vaccinated group, 24 (64.9%) children were aged 0–6 months, 12 (32.4%) were aged 6–12 months, and only one (2.7%) was older than 12 months. In contrast, among children born to unvaccinated mothers, 19 (36%) were aged 0–6 months, 8 (15%) were aged 6–12 months, and 26 (49%) were older than 12 months.
However, the number of infants younger than 2 months with RSV infection was lower in the vaccinated group than in the unvaccinated group (4 vs 11 children).
Thus, among infants and children whose mothers had received the RSV vaccine, almost all admissions (97.3%) occurred before 12 months of age. In contrast, almost half of admissions (49%) in the unvaccinated group occurred in children older than 12 months.
Children whose mothers had received the RSV vaccine appeared to require less respiratory support overall. The proportion requiring no respiratory support was higher in the vaccinated group than in the unvaccinated group (62.2% vs 49%).
Low-flow oxygen was required in 27.0% of children in the vaccinated group compared with 36% in the unvaccinated group. Similarly, AIRVO (high-flow nasal oxygen) was required in 10.8% of children in the vaccinated group compared with 15% in the unvaccinated group.
There was a statistically significant association between vaccination status and length of hospital stay (χ² = 12.83, p = 0.0016). Children whose mother had received the vaccine were more likely to have a hospital stay of <1 day (59.5% vs 24.5%), whereas children whose mother hadn’t received the vaccine were more likely to have a stay of >3 days (50.9% vs 18.9%).
Limitations
This was an observational analysis, and potential confounding factors were not included, including prematurity, underlying comorbidities and the timing of maternal RSV vaccination. The difference in age distribution between the two groups may have influenced the results.
Conclusions
Children born to mothers who received the RSV vaccine appeared to require less respiratory support and had statistically significant shorter hospital stays. Fewer children in the vaccinated group appeared to require escalation to AIRVO, suggesting a potential reduction in the severity of bronchiolitis.
These findings suggest an association between maternal RSV vaccination and reduced disease severity and healthcare utilisation.

